Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-052085
Date:2021-08-13
Issuer: TRAVERE THERAPEUTICS, INC. (TVTX)
Original Submission Date:

Reporting Person:

HEERMA PETER
C/O RETROPHIN, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-08-13 A 4,500 a $0.00 64,922 direct
COMMON STOCK 2021-08-17 S 1,407 d $17.12 63,515 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 on january 31, 2020, the reporting person was granted a performance restricted stock unit (prsu) grant covering 9,000 shares of the issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. on august 13, 2021, a portion of the prsus vested upon the issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the protect study.
f2 includes 1,078 shares of the issuer's common stock acquired by the reporting person on may 31, 2021 pursuant to an employee stock purchase program.
f3 represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. this sale is mandated by the issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the issuer. this sale does not represent a discretionary trade by the reporting person.
WhaleWisdom Logo

Elevate your investments